SCHEMBL1492859

SCHEMBL1492859

CCOC(=O)C(C)(C)Cc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 2/20 0.65
ALDH1A1 P00352 3/20 0.60
RECQL P46063 1/20 0.60
PIN1 Q13526 1/20 0.51
PPID Q08752 1/20 0.46
POLB P06746 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TAAR1 Q96RJ0 3/20 0.44
LMNA P02545 2/20 0.44
THRB P10828 1/20 0.44
RIPK1 Q13546 3/20 0.44
MAPT P10636 1/20 0.43
HIF1A Q16665 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SLC6A2 P23975 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15669148 0.87 L3MBTL1 (0.56) MMP8ALDH1A1RECQLLMNAMAPT
SCHEMBL28371759 0.86 ALDH1A1 (0.56) MMP8ALDH1A1RECQLSMN1; SMN2LMNA
SCHEMBL13170332 0.86 MMP8 (0.49) MMP8ALDH1A1RECQLPIN1NPSR1
SCHEMBL8710582 0.86 MMP8 (0.79) MMP8ALDH1A1RECQLPIN1PPID
SCHEMBL6746893 0.85 MMP8 (0.49) MMP8ALDH1A1RECQLPIN1TSHR
SCHEMBL12574782 0.84 MMP8 (0.63) MMP8ALDH1A1RECQLPIN1PPID
SCHEMBL22070681 0.84 MMP8 (0.48) MMP8ALDH1A1RECQLPIN1PPID
SCHEMBL10821760 0.84 MMP8 (0.63) MMP8ALDH1A1RECQLPIN1PPID
SCHEMBL8486868 0.84 ESR1 (0.50) MMP8ALDH1A1RECQLTSHR
SCHEMBL11172538 0.84 PPARA (0.51) MMP8ALDH1A1RECQLTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10238592-B2 Organic compounds GIVAUDAN S.A. (CH) 2019-03-26 US claimed
US-20170181945-A1 Improvements in or Relating to Organic Compounds GIVAUDAN S.A. (CH) 2017-06-29 US claimed
EP-3137049-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2017-03-08 EP claimed
WO-2015165582-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2015-11-05 WO claimed
EP-3416729-B1 PRO-FRAGRANCE COMPOSITION AQDOT LTD (GB) 2023-09-20 EP disclosed
CN-115916935-A Granular laundry detergent additive 宝洁公司 2023-04-04 CN disclosed
US-10695277-B2 Pro-fragrance composition AQDOT LIMITED (GB) 2020-06-30 US disclosed
US-10696617-B2 Method for alcoholysis of amide ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) 2020-06-30 US disclosed
US-10696617-B2 Method for alcoholysis of amide ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) 2020-06-30 US disclosed
US-20200055807-A1 METHOD FOR ALCOHOLYSIS OF AMIDE ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) 2020-02-20 US disclosed
US-20200055807-A1 METHOD FOR ALCOHOLYSIS OF AMIDE ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) 2020-02-20 US disclosed
US-10238592-B2 Organic compounds GIVAUDAN S.A. (CH) 2019-03-26 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
CN-101014578-A Triazole derivative or salt thereof ASTELLAS PHARMA INC (JP) 2007-08-08 CN disclosed
CN-1043042-C Cephalosporins derivatives and process for preparing them HOECHST AG (DE) 1999-04-21 CN disclosed
US-RE34865-E Antibiotics HOECHST AKTIENGESELLSCHAFT (DE) 1995-02-21 US disclosed
US-5100887-A Bactericides HOECHST AKTIENGESELLSCHAFT (DE) 1992-03-31 US disclosed
CN-1035509-A Cynnematin analog derivative and preparation method thereof HOECHST AG (DE) 1989-09-13 CN disclosed
EP-0329008-A2 Cephalosporinderivatives and process for its preparation HOECHST AKTIENGESELLSCHAFT (DE) 1989-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055807-A1 METHOD FOR ALCOHOLYSIS OF AMIDE ADH1A, ADH5, ADH1C MMP8 269/4885ALDH1A1 43/4885RECQL 4201/4885
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MAP4K5, MAP3K5, MAP4K2 MMP8 3717/4885ALDH1A1 3788/4885RECQL 2804/4885
US-10696617-B2 Method for alcoholysis of amide ADH5, ADH1A, ADH1C MMP8 513/4885ALDH1A1 91/4885RECQL 3942/4885
US-10695277-B2 Pro-fragrance composition COPS5, COPS8, CBR3 MMP8 2488/4885ALDH1A1 1526/4885RECQL 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.